CoChat
Sign Up
Cited by 273T-cell and B-cell ImmunologyPsoriasis: Treatment and PathogenesisCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 114 of the 116 references it cites were found in a registry or an index.

CD3(+)CD4(-)CD8(-) (Double-negative) T cells in inflammation, immune disorders and cancer

Open access
Wu, Zhiheng, Zheng, Yu, Sheng, Jin, Han, Yicheng, Yang, Yanyan, Pan, Hongming, Yao, Junlin·2022·Frontiers in Immunology
DOI 10.3389/fimmu.2022.816005PMC PMC8866817
Open this paper in CoChat — free account

Abstract

double-negative (DN) T cells, although constituting a rare subset of peripheral T cells, are gaining interest for their roles in inflammation, immune disease and cancer. Herein, we comprehensively review the origin, distribution and functions of this unique T cell subgroup. First, we focused on characterizing multifunctional DN T cells in various immune responses. DN regulatory T cells have the capacity to prevent graft-versus-host disease and have therapeutic value for autoimmune disease. T helper-like DN T cells protect against or promote inflammation and virus infection depending on the specific settings and promote certain autoimmune disease. Notably, we clarified the role of DN tumor-infiltrating lymphocytes and outlined the potential for malignant proliferation of DN T cells. Finally, we reviewed the recent advances in the applications of DN T cell-based therapy for cancer. In conclusion, a better understanding of the heterogeneity and functions of DN T cells may help to develop DN T cells as a potential therapeutic tool for inflammation, immune disorders and cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2022.816005

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic diagram of DN T cell origin and distribution. Progenitor cells from the bone marrow colonize the corticomedullary junction of the thymus and generate the T cell lineage. In the DN3 stage, generally, high TCR strength makes TCRγδ+ DN thymocytes remain “double-negative”, whereas low TCR strength induces DN thymocytes with pre-TCRs to follow the αβ lineage fate. A small number of DP thymocytes differentiate into two distinct mature DN thymocyte subsets rather than entering the late SP stage: DN thymocytes selected by very strong TCR-MHC interactions preferentially migrate to the intestine where they re-express CD8α and are sequestered as CD8αα+ intraepithelial lymphocytes, while DN thymocytes selected by very weak TCR-MHC interactions become precursors to peripheral TCRαβ+ DN T cells. In peripheral circulation, CD4+/CD8+ T cells can also convert into DN T cells by downregulating CD4/CD8 expression. Peripheral DN T cells are localized in various organs in mice and humans. αβ, alpha and beta; Ag, antigen; DN, double-negative; DP, double-positive; γδ, gamma and delta; ISP, immature single-positive; MHC, major histocompatibility complex; SP, single-positive; TCR, T cell receptor.
Figure 1 Schematic diagram of DN T cell origin and distribution. Progenitor cells from the bone marrow colonize the corticomedullary junction of the thymus and generate the T cell lineage. In the DN3 stage, generally, high TCR strength makes TCRγδ+ DN thymocytes remain “double-negative”, whereas low TCR strength induces DN thymocytes with pre-TCRs to follow the αβ lineage fate. A small number of DP thymocytes differentiate into two distinct mature DN thymocyte subsets rather than entering the late SP stage: DN thymocytes selected by very strong TCR-MHC interactions preferentially migrate to the intestine where they re-express CD8α and are sequestered as CD8αα+ intraepithelial lymphocytes, while DN thymocytes selected by very weak TCR-MHC interactions become precursors to peripheral TCRαβ+ DN T cells. In peripheral circulation, CD4+/CD8+ T cells can also convert into DN T cells by downregulating CD4/CD8 expression. Peripheral DN T cells are localized in various organs in mice and humans. αβ, alpha and beta; Ag, antigen; DN, double-negative; DP, double-positive; γδ, gamma and delta; ISP, immature single-positive; MHC, major histocompatibility complex; SP, single-positive; TCR, T cell receptor.CC BY · PubMed Central
Figure 2 DN T cells participate in both innate and adaptive immunity. Based on Ag-TCR-specific recognition, DN T cells can inhibit or eliminate adaptive immune cells, suppressing diseases caused by immune responses. DN T cells can also secrete various cytokines to mediate innate immune responses. Ag, antigen; APC, antigen presenting cell; CXCL, chemokine ligand; DN, double-negative; IFN-γ, interferon-γ; IL, interleukin; M. tuberculosis, Mycobacterium tuberculosis; TCR, T cell receptor; TNF, tumor necrosis factor.
Figure 2 DN T cells participate in both innate and adaptive immunity. Based on Ag-TCR-specific recognition, DN T cells can inhibit or eliminate adaptive immune cells, suppressing diseases caused by immune responses. DN T cells can also secrete various cytokines to mediate innate immune responses. Ag, antigen; APC, antigen presenting cell; CXCL, chemokine ligand; DN, double-negative; IFN-γ, interferon-γ; IL, interleukin; M. tuberculosis, Mycobacterium tuberculosis; TCR, T cell receptor; TNF, tumor necrosis factor.CC BY · PubMed Central
Figure 3 Cell surface molecules or cytokines expressed by DN TILs show debatable antitumor or tumor-promoting activity during tumor development. DN, double-negative; TIL, tumor-infiltrating lymphocyte.
Figure 3 Cell surface molecules or cytokines expressed by DN TILs show debatable antitumor or tumor-promoting activity during tumor development. DN, double-negative; TIL, tumor-infiltrating lymphocyte.CC BY · PubMed Central
Figure 4 Mechanisms of DN T cells in cancer treatment. (A) The killing effect of DN T cells toward AML cells can be perforin/granzyme B-dependent; IFN-γ enhances the effect of NKG2D and DNAM-1 in the DN T cell-mediated inhibition of AML cells. (B) NKG2D, DNAM-1 and soluble TRAIL participate in DN T cell-mediated lysis of NSCLC cells. (C) DN T cells eliminate pancreatic tumor cells through the Fas/FasL pathway. AML, acute myeloid leukemia; DN, double-negative; DNAM-1, DNAX accessory molecule-1; DNAM-1L, DNAX accessory molecule-1 ligand; FADD, Fas-associating protein with a novel death domain; FasL, Fas ligand; IFN-γ, interferon-γ; IFN-R, interferon receptor; NKG2D, natural-killer group 2, member D; NKG2DL, natural-killer group 2, member D ligand; NSCLC, non-small-cell lung cancer; TNF, tumor necrosis factor; TNF-R, tumor necrosis factor receptor; TRAIL, TNF-related apoptosis-inducing ligand; TRAIL-R, TNF-related apoptosis-inducing ligand receptor.
Figure 4 Mechanisms of DN T cells in cancer treatment. (A) The killing effect of DN T cells toward AML cells can be perforin/granzyme B-dependent; IFN-γ enhances the effect of NKG2D and DNAM-1 in the DN T cell-mediated inhibition of AML cells. (B) NKG2D, DNAM-1 and soluble TRAIL participate in DN T cell-mediated lysis of NSCLC cells. (C) DN T cells eliminate pancreatic tumor cells through the Fas/FasL pathway. AML, acute myeloid leukemia; DN, double-negative; DNAM-1, DNAX accessory molecule-1; DNAM-1L, DNAX accessory molecule-1 ligand; FADD, Fas-associating protein with a novel death domain; FasL, Fas ligand; IFN-γ, interferon-γ; IFN-R, interferon receptor; NKG2D, natural-killer group 2, member D; NKG2DL, natural-killer group 2, member D ligand; NSCLC, non-small-cell lung cancer; TNF, tumor necrosis factor; TNF-R, tumor necrosis factor receptor; TRAIL, TNF-related apoptosis-inducing ligand; TRAIL-R, TNF-related apoptosis-inducing ligand receptor.CC BY · PubMed Central
Figure 5 The summary of multifunctional DN T cells in inflammation, immune disorders and cancer. DN T cells exert both regulatory and helper-like functions under different conditions and can exert antitumor activity in cancer treatment. DN, double-negative.
Figure 5 The summary of multifunctional DN T cells in inflammation, immune disorders and cancer. DN T cells exert both regulatory and helper-like functions under different conditions and can exert antitumor activity in cancer treatment. DN, double-negative.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 116 references

Cited by

Sorted by citations

See all 273

Related

Metadata

Authors
Wu, Z., Zheng, Y., Sheng, J., Han, Y., Yang, Y., Pan, H., & Yao, J.
Affiliations
Sir Run Run Shaw Hospital (CN)
Corresponding author
  • Pan, Hongming
  • Yao, Junlin
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2022-02-10
Volume
13
Pages
816005-816005
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2022.816005
PMC
PMC8866817
OpenAlex
W4211100870
Cited by
265
References
116
Citations by year
2026: 38 · 2025: 90 · 2024: 75 · 2023: 47 · 2022: 14
FWCI
6.14
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81803070, 81702809)
  • Natural Science Foundation of Zhejiang Province (LSY19H160006)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
double-negative T cells, CD3+CD4-CD8- T cells, regulatory T cells, graft-versus-host disease, autoimmune disease, inflammation, viral infection, tumor-infiltrating lymphocytes, T cell heterogeneity
MeSH terms
Autoimmune Diseases, Graft vs Host Disease, Humans, Inflammation, Neoplasms, CD8 Antigens, CD8-Positive T-Lymphocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review